Targeting Kinase Suppressor of Ras 1 (KSR1) for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Signal Transduction

Background:

• Carcinogenesis involves dysregulated signaling pathways like RAS/RAF/MEK/ERK (RAS/MAPK).
• BRAF and MEK inhibitors show success but face adaptive resistance, necessitating exploration of other pathway targets.
• Kinase suppressor of Ras 1 (KSR1), a scaffold protein, is increasingly recognized as an active regulator of RAS/MAPK signaling.

Purpose of the Study:

• To provide a comprehensive review of accessory and scaffold proteins in the RAS/MAPK pathway.
• To focus on the structural and functional properties of KSR1.
• To summarize preclinical evidence and discuss the therapeutic potential of KSR1-targeted interventions in cancer, particularly hepatocellular carcinoma (HCC).

Main Methods:

• Literature review focusing on RAS/MAPK pathway components and KSR1.
• Analysis of preclinical data on KSR1 function and inhibition.
• Synthesis of information on KSR1's role in cancer proliferation and survival.

Main Results:

• KSR1 overexpression promotes cancer cell proliferation and survival.
• Inhibition of KSR1 attenuates RAS/MAPK signaling and suppresses tumor growth in preclinical models.
• KSR1 is a promising therapeutic target for various cancers.

Conclusions:

• KSR1 is a critical regulator of RAS/MAPK signaling and a potential therapeutic target.
• Targeting KSR1 offers a strategy to overcome resistance to existing therapies.
• Further investigation into KSR1-based therapies, especially for HCC, is warranted.